Lonza buys Micro-Macinazione to bolster micronization biz

By Gareth Macdonald contact

- Last updated on GMT

iStock/herraez
iStock/herraez

Related tags: Better

Lonza Group AG has acquired API processing firm Micro-Macinazione SA from private equity investor Cross Equity SA.  

The takeover – which was completed on July 26 – includes Micro-Macinazione’s active pharmaceutical ingredient (API) processing site and recently expanded​ warehouse in Monteggio, Switzerland.

A Lonza spokesman told us: “Micro-Macinazione has 120 employees and is based in Monteggio, Switzerland. We will take over the entire site.

He added that: “Micro-Macinazione provides micronization technology and expertise that complements our existing US capabilities and provides significant additional capacity to support our growth​.”

Lonza said demand for micronization and sub-micronization is increasing as customers seek to improve the bioavailability and efficacy of their products.

The Swiss life science supplier’s main drug ingredient micronization capabilities are located at a facility in Quakertown, Pennsylvania that is owned by recent acquisition Capsugel​.

News of the acquisition comes a little over a year​ after Capsugel said it planned to increase micronization capacity at the Quakertown site.

Small molecules, major driver

In July Lonza predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022 citing the expansion of its offering provided by Capsugel as an important driver.

The firm reported that its harma&biotech segment generated revenue of CHF1.06bn in the first half of 2017, up 27% on the equivalent period last year.

It cited “positive performance within chemical manufacturing” adding that “Small molecules made a significant improvement compared to the prior year due to better commercial offerings to existing and new customers.”

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us

Products

View more

Webinars